Evidence map›Paper›PMID 28827549›Full record

ArticleScientific reports2017

Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS.

E Taskesen, A Mishra, S van der Sluis, R Ferrari, International FTD-Genomics Consortium, J H Veldink, M A van Es, A B Smit, D Posthuma, Y Pijnenburg

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. "Assessing relationship between blood MAPT methylation levels and clinical expression in Frontotemporal Dementia".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Observational
  2. Article
  3. DNA methylation as a contributor to dysregulation ofbioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Blood-based multivariate methylation risk score for cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  10. Article
  11. Article
  12. [Abnormal transfer RNA epigenetic modifications and related impact on neurodegenerative diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Cancer management and research · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 20 institutions in 12 countries.

E TaskesenVU University Amsterdam, Center for Neurogenomics and Cognitive Research, Complex Trait Genetics (CTG), Amsterdam Neuroscience, Amsterdam, The Netherlands.
A MishraVU University Amsterdam, Center for Neurogenomics and Cognitive Research, Complex Trait Genetics (CTG), Amsterdam Neuroscience, Amsterdam, The Netherlands.
S van der SluisVU University Amsterdam, Center for Neurogenomics and Cognitive Research, Complex Trait Genetics (CTG), Amsterdam Neuroscience, Amsterdam, The Netherlands.
R FerrariUCL London, Institute of Neurology, Department of Molecular Neuroscience, London, UK.
International FTD-Genomics Consortium
J H VeldinkDepartment of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
M A van EsDepartment of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
A B SmitVU University Amsterdam, Center for Neurogenomics and Cognitive Research, Department of Molecular and Cellular Neurobiology (MCN), Amsterdam Neuroscience, Amsterdam, The Netherlands.
D PosthumaVU University Amsterdam, Center for Neurogenomics and Cognitive Research, Complex Trait Genetics (CTG), Amsterdam Neuroscience, Amsterdam, The Netherlands.
Y PijnenburgVU University Medical Center (VUMC), Alzheimer Center, Amsterdam Neuroscience, Amsterdam, The Netherlands. YAL.Pijnenburg@vumc.nl.
University College London · GBNeuroscience Research Australia · AUAmsterdam Neuroscience · NLMayo Clinic · USSaarland University · DEClinica Universidad de Navarra · ESInserm · FRNational Institute on Aging · USNewcastle Hospitals - Campus for Ageing and Vitality · GBUniversity of California, San Francisco · USUniversity of Florence · ITUniversity of Manchester · GBCentro San Giovanni di Dio Fatebenefratelli · ITErasmus University Rotterdam · NLFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITFundació ACE · ESJacksonville College · USLund University · SETechnical University of Munich · DE

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Characterization of Normal Genomic VariabilityZIAAG000932 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$11.3M
The Frontotemporal Lobar Degeneration Neuroimaging InitiativeR01AG032306 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2009 to 2013
$10.0M
Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Neural Basis of Generalized QuantifiersR01NS044266 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GROSSMAN, MURRAY · 2004 to 2014
$6.8M
Intramural NIH HHS Z01 AG000932Intramural NIH HHS ZIA AG000932Medical Research Council G0301152Medical Research Council G0400074Medical Research Council G0502157Medical Research Council G0802462Medical Research Council G0900652Medical Research Council G0901254Medical Research Council G1100540Medical Research Council MC_U105597119Medical Research Council MC_U123160651Medical Research Council MC_UU_00005/12Medical Research Council MC_UU_00024/1NIA NIH HHS K23 AG000932NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P01 AG026276NIA NIH HHS P01 AG032953NIA NIH HHS P30 AG010124NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG037491NINDS NIH HHS P30 NS069329NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS044266NINDS NIH HHS R01 NS065782NINDS NIH HHS R01 NS080882Wellcome Trust
6 · The paper itself

Abstract

Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting the frontal and temporal lobes. Genome-wide association studies (GWAS) on FTD identified only a few risk loci. One of the possible explanations is that FTD is clinically, pathologically, and genetically heterogeneous. An important open question is to what extent epigenetic factors contribute to FTD and whether these factors vary between FTD clinical subgroup. We compared the DNA-methylation levels of FTD cases (n = 128), and of FTD cases with Amyotrophic Lateral Sclerosis (FTD-ALS; n = 7) to those of unaffected controls (n = 193), which resulted in 14 and 224 candidate genes, respectively. Cluster analysis revealed significant class separation of FTD-ALS from controls. We could further specify genes with increased susceptibility for abnormal gene-transcript behavior by jointly analyzing DNA-methylation levels with the presence of mutations in a GWAS FTD-cohort. For FTD-ALS, this resulted in 9 potential candidate genes, whereas for FTD we detected 1 candidate gene (ELP2). Independent validation-sets confirmed the genes DLG1, METTL7A, KIAA1147, IGHMBP2, PCNX, UBTD2, WDR35, and ELP2/SLC39A6 among others. We could furthermore demonstrate that genes harboring mutations and/or displaying differential DNA-methylation, are involved in common pathways, and may therefore be critical for neurodegeneration in both FTD and FTD-ALS.

Identifiers

PMID28827549
PMCPMC5567187
OpenAlexW2750320785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.